Close Menu


The Phase I/II GOBLET trial will assess pelareorep plus Tecentriq in pancreatic, colorectal, and anal cancer patients and explore biomarkers of response.

The study will assess the safety and anti-tumor activity of the IL-7 agent and the checkpoint inhibitor combination for patients with PD-L1-expressing NSCLC. 

Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.

The Swiss company will assess the agent both alone and combined with Tecentriq as a treatment for FGFR-positive gastric cancer.

The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.

The statement is based on the IMpassion131 trial, in which the combination did not improve survival endpoints compared to paclitaxel in PD-L1-positive patients.

The drug giant is discussing the data from Impassion131 with regulators and will use the insights from the trial to inform future studies.

The approval is based on the results from the Phase III IMspire150 study, in which patients treated with the three-drug combination had an improvement in progression-free survival.

In a Phase Ia/Ib study, the anti-TIGIT antibody and Tecentriq combination had better anti-tumor activity than tiragolumab alone, particularly in PD-L1 expressing lung cancers.

Investigators saw responses in one colorectal cancer and one breast cancer patient and are now studying differences between responders and non-responders.